Evidence map›Paper›PMID 36694381›Full record

ArticleObesity (Silver Spring, Md.)2023

Rising NAFLD and metabolic severity during the Sars-CoV-2 pandemic among children with obesity in the United States.

Aaron L Slusher, Pamela Hu, Stephanie Samuels, Fuyuze Tokoglu, Jessica Lat, Zhongyao Li, Michele Alguard, Jordan Strober, Daniel Vatner, Veronika Shabanova and 1 more

Open access · greenAbstract read
In one paragraph

Article in Obesity (Silver Spring, Md.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. COVID-19 and Fatty Liver Disorders.Journal of clinical medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Aaron L SlusherDepartment of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0003-2082-4827
Pamela HuDepartment of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
Stephanie SamuelsDepartment of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-0873-9841
Fuyuze TokogluRadiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, USA.
Jessica LatDepartment of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
Zhongyao LiDepartment of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
Michele AlguardDepartment of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
Jordan StroberDepartment of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Daniel VatnerDepartment of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0003-2073-0273
Veronika ShabanovaDepartment of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
Sonia CaprioDepartment of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
Yale University · US

Funding

DIABETES MELLITUS &DISORDERS OF METABOLISMT32DK007058 · NIDDK · YALE UNIVERSITY · PI SONIA CAPRIO, Kevan C Herold · 1986 to 2026
$9.6M
METABOLIC PREDICTORS AND MARKERS OF CHILDHOOD OBESITYR01HD028016 · NICHD · YALE UNIVERSITY · PI CAPRIO, SONIA · 1991 to 2024
$8.9M
Pathogenesis of youth onset pre-diabetes and Type 2 diabetesR01DK111038 · NIDDK · YALE UNIVERSITY · PI CAPRIO, SONIA · 2016 to 2025
$7.0M
Metabolic heterogeneity underlying hypertriglyceridemia in insulin resistanceR01DK124272 · NIDDK · YALE UNIVERSITY · PI VATNER, DANIEL · 2020 to 2024
$2.3M
NICHD NIH HHS R01 HD028016NIDDK NIH HHS R01 DK111038NIDDK NIH HHS R01 DK124272NIDDK NIH HHS T32 DK007058
6 · The paper itself

Abstract

objectiveNonalcoholic fatty liver disease (NAFLD), the most common liver disease among youth with obesity, precedes more severe metabolic and liver diseases. However, the impact of the Sars-CoV-2 global pandemic on the prevalence and severity of NAFLD and the associated metabolic phenotype among youth with obesity is unknown.

methodsParticipants were recruited from the Yale Pediatric Obesity Clinic during the Sars-CoV-2 global pandemic (August 2020 to May 2022) and were compared with a frequency-matched control group of youth with obesity studied before the Sars-CoV-2 global pandemic (January 2017 to November 2019). Glucose metabolism differences were assessed during an extended 180-minute oral glucose tolerance test. Magnetic resonance imaging-derived proton density fat fraction (PDFF) was used to determine intrahepatic fat content in those with NAFLD (PDFF ≥ 5.5).

resultsNAFLD prevalence increased in participants prior to (36.2%) versus during the Sars-CoV-2 pandemic (60.9%), with higher PDFF values observed in participants with NAFLD (PDFF ≥ 5.5%) during versus before the pandemic. An increase in visceral adipose tissue and a hyperresponsiveness in insulin secretion during the oral glucose tolerance test were also observed.

conclusionsHepatic health differences were likely exacerbated by environmental and behavioral changes associated with the pandemic, which are critically important for clinicians to consider when engaging in patient care to help minimize the future risk for metabolic perturbations.

Indexed as

COVID-19Non-alcoholic Fatty Liver DiseaseHumansLiverMagnetic Resonance ImagingObesityPandemicsSARS-CoV-2United States

Identifiers

PMID36694381
PMCPMC10186584
OpenAlexW4318027625

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.